The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum and supportive policy tailwinds. This combination is setting the stage for ...

AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Biotech firms use AI in trials to target patients more ...

Up to $39.1 million was held in companies that benefited from a provision of Republicans' 2025 tax and spending law. With a sports car that somersaults through the air, Elon Musk is back in the ...

I reiterate a Hold rating on State Street SPDR S&P Biotech ETF due to fair valuation and mixed technicals. XBI's recent outperformance has faded, with higher interest rates and a less risk-on market ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector's two major indexes - the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) - ...